Zealand CEO sees competitive edge over Novo
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article7575831.ece/ALTERNATES/schema-16_9/Britt%2520Meelby%2520Jensen2.jpg)
“It’s a really, really important milestone for Zealand Pharma and something we have waited for and looked forward to for a long time,” says Zealand Pharma CEO Britt Meelby Jensen after her company announced Big Pharma partner Sanofi had won US approval of diabetes product Soliqua.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand's big money dreams can finally come true
For abonnenter
Welcome news for Novo as diabetes combo wins US approval
For abonnenter
Novo EVP: Negotiations can begin now
For abonnenter